Skip to content

Evaluation of letrozole and letrozole combined with gonadotropin sequential treatment for ovulation induction in infertile patients with polycystic ovary syndrome: a randomized controlled trial

Evaluation of letrozole and letrozole combined with gonadotropin sequential treatment for ovulation induction in infertile patients with polycystic ovary syndrome: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022971
Enrollment
Unknown
Registered
2019-05-05
Start date
2019-05-20
Completion date
Unknown
Last updated
2019-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Interventions

Group A:Letrozole is taken orally on the third to seventh day of the menstrual cycle
Group B:Letrozole is taken orally on the 3rd to 7th day of the menstrual cycle, and gonadotropin is intramuscularly injected on the 8th to 10th day

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. PCOS patients meeting the 2003 Rotterdam diagnostic criteria: (1) patients with rare ovulation or even no ovulation; (2) clinical symptoms or biochemical manifestations of patients show hyperandrogenemia; (3) polycystic changes of the ovary can be seen on abdominal color ultrasound (vaginal color ultrasound shows that one or both ovaries contain more than 12 follicles of 2-9mm); A diagnosis can be made if two of the above three criteria are met. 2. less than 40 years old, normal sex life, infertility course for more than 1 year; 3. hysterosalpingography indicated that the uterine morphology was normal, and at least one side of the fallopian tube was unobstructed; 4. there was no abnormal or mild oligospermia or asthenospermia in the sperm analysis results of the spouses; 5. all organs function normally, without any endocrine disorders, such as hypophysis, hyperthyroidism, etc.

Exclusion criteria

Exclusion criteria: (1) those who are known to be allergic to relevant drugs; (2) patients with mental or neurological diseases cannot actively cooperate with the experiment; (3) patients with severe cardiovascular and hepatic and renal dysfunction; (4) pregnant and lactating women; (5) have a history of abnormal diseases of uterus or uterine cavity; (6) previous exposure to teratogenic substances, radiation, etc.

Design outcomes

Primary

MeasureTime frame
pregnancy rate;ovulation rate;

Secondary

MeasureTime frame
single pregnancy rate;the level of estradiol on the day of HCG injection;the level of progesterone on the day of HCG injection;the level of luteinizing hormone on the day of HCG injection;endometrial thickness on the day of HCG injection;the number of mature follicles;the rate of ectopic pregnancy;the rate of early abortion;the rate of OHSS;mutiple pregnancy rate;

Countries

China

Contacts

Public ContactYi Liu

Union Hospital, Tongji Medical College,Huazhong University of Science and Technology

liqun94@163.com+86 13971038710

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026